2 documents found, page 1 of 1
Peginterferon still has a place in the treatment of hepatitis C caused by genot...
Grando, Aline Vitali; Ferreira, Paulo Roberto Abrão; Pessôa, Mário Guimarães; Mazo, Daniel Ferraz de Campos; Brandão-Mello, Carlos EduardoDespite recent advances in therapy for chronic hepatitis C (CHC), the disease caused by genotype 3 virus (GEN3) is still considered a treatment challenge in certain patient subgroups. The aim of this retrospective study was to evaluate the effectiveness and safety of the peginterferon (Peg-IFN) and ribavirin (RBV) combination treatment for GEN3/CHC patients, and to evaluate sustained virological response (SVR) ...
Effectiveness and safety of first-generation protease inhibitors in real-world ...
Callefi, Luciana Azevedo; Villela-Nogueira, Cristiane Alves; de Barros Tenore, Simone; Carnaúba-Júnior, Dimas; Coelho, Henrique Sérgio MoraesOBJECTIVE: To evaluate the effectiveness and safety of first-generation protease inhibitors for the treatment of genotype 1 hepatitis C virus-infected patients at Brazilian reference centers. METHODS: This multicenter cross-sectional study included hepatitis C virus genotype 1 monoinfected patients treated with Peg-interferon, ribavirin, and either boceprevir (n=158) or telaprevir (n=557) between July 2013 and ...